Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Cost cuts are coming for Allergan, CEO Brent Saunders says
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 5957596"]"What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The </p><p>Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will."</p><p><br /></p><p>Imprimis is not the biggest threat to Restasis by a long shot. Imprimis is a small compound pharmacy. They are trying to ride the coat tails of Restasis news but they can't make Restasis. They can compound Cyclosporine eye drops that aren't commercially available and only then if a doctor specifically requests for a patient based on a medical need (allergic to an ingredient or something). I don't know about you but I have never in my lifetime for me or any family member had a doctor prescribe a drug that required compounding. The market share for compound drugs is small. </p><p><br /></p><p>The biggest threat to Restasis is the loss of the patent exclusivity and the entry of other dry eye medications. I agree that Allergan will continue to try and protect the Restasis franchise.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 5957596"]"What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will." Imprimis is not the biggest threat to Restasis by a long shot. Imprimis is a small compound pharmacy. They are trying to ride the coat tails of Restasis news but they can't make Restasis. They can compound Cyclosporine eye drops that aren't commercially available and only then if a doctor specifically requests for a patient based on a medical need (allergic to an ingredient or something). I don't know about you but I have never in my lifetime for me or any family member had a doctor prescribe a drug that required compounding. The market share for compound drugs is small. The biggest threat to Restasis is the loss of the patent exclusivity and the entry of other dry eye medications. I agree that Allergan will continue to try and protect the Restasis franchise.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Cost cuts are coming for Allergan, CEO Brent Saunders says
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Cost cuts are coming for Allergan, CEO Brent Saunders says
>